观察高低氧放疗对Ⅰ-Ⅲ期食管癌的临床疗效

To Observe the Clinical Effect of High Hypoxia Radiotherapy on Stage Ⅰ to Ⅲ Esophageal Carcinoma

目的针对Ⅰ-Ⅲ期食管癌患者采用高低氧放疗进行治疗的实际效果进行分析。方法在本院于2014年5月-2016年5月所接收的Ⅰ-Ⅲ期食管癌患者中任选100例,盲选组内50例患者按照常规方式进行化疗治疗,作为对照组,另50例患者则给予高低氧放疗治疗,为观察组。针对两组患者疗效间差异进行对比。结果在本次研究中,观察组中27例患者完全缓解,20例患者部分缓解,仅3例患者无明显变化,而对照组中完全缓解为20例,部分缓解为20例,10例患者无明显变化,观察组明显优于对照组(P<0.05),差异具备统计学意义。在治疗过程中,观察组19例患者出现不良反应,对照组18例患者出现不良反应,不存在有显著差异(P>0.05),差异无统计学意义。通过为期1年追踪调查可以发现,观察组6例患者死亡,而对照组为14例,观察组生存率明显高于对照组(P<0.05),差异具备统计学意义。结论针对Ⅰ-Ⅲ期食管癌患者采用高低氧放疗治疗,能有效提升临床针对该部分患者的诊治效率,提升患者远期生存率,可作为临床对于该部分患者的首选诊治方案。

Objective To analyze the effect of high hypoxia radiotherapy on patients with stage Ⅰ to Ⅲ esophageal cancer. MethodsIn our hospital from May 2014 to May 2016 received Ⅰ-Ⅲ period in patients with esophageal cancer in the optional 100 cases, blind group selection in 50 cases of chemotherapy according to the conventional way, as the control group, the other 50 patients were given CPLCOR treatment, as the observation group. The difference between the two groups of patients was compared. Results In this study, 27 patients in the observation group complete remission, partial remission in 20 patients, only 3 patients had no obvious change, while the control group was 20 cases of complete remission, partial remission in 20 cases, 10 cases had no obvious change, the observation group was significantly better than the control group(P<0.05),the difference has statistical significance. In the treatment process, the observation group of 19 patients with adverse reactions, the control group of 18 patients with adverse reactions, there is no significant difference( P>0.05),difference is not statistically significant. Through 1 years of follow-up survey, we can find that the observation group of 6 patients died, while the control group was 14 cases, the survival rate of the observation group was significantly higher than that of the control group of(P<0.05),and the difference was statistically significant. Conclusion For Ⅰ-Ⅲ patients with esophageal cancer using CPLCOR treatment, can effectively improve the clinical efficiency in the diagnosis and treatment of patients with, improve long-term survival in patients with clinical diagnosis and treatment, can be used as the first choice for the scheme of the part of the patients.